SPIOLTO Respimat (tiotropium/olodaterol) product box.

SPIOLTO® Respimat®

Tiotropium/olodaterol

SPIOLTO® Respimat®

Product Overview

SPIOLTO® Respimat® (tiotropium/olodaterol) is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).1

SPIOLTO Respimat (tiotropium/olodaterol) product box.

Quick links

Quick links

Mechanism of Action

SPIOLTO® Respimat® is a fixed dose combination inhalation solution containing the long-acting muscarinic receptor antagonist (LAMA), tiotropium and the long-acting beta antagonist (LABA), olodaterol which is delivered via the SPIOLTO® Respimat® soft mist inhaler device.1 The two active ingredients provide additive bronchodilation due to their different modes of action. Since muscarinic receptors appear to be more prominent in the central airways while beta2-adrenoceptors have a higher expression level in the peripheral airways, a combination of tiotropium and olodaterol should provide optimal bronchodilatation in all regions of the lungs.

Tiotropium - Tiotropium bromide is a long-acting, specific antagonist at muscarinic receptors.1

Olodaterol - Olodaterol has a high affinity and high selectivity to the human beta2-adrenoceptor.1

Explore how your COPD patients can benefit from SPIOLTO® Respimat® in COPD

Product Key Facts

Indication

Chronic obstructive pulmonary disease (COPD)

Active ingredients

Tiotropium/olodaterol

Legal category

Prescription only medicine

Strength

2.5 micrograms tiotropium/2.5 micrograms olodaterol per puff
The recommended dose is 5 microgram tiotropium and 5 microgram olodaterol given as two puffs from the Respimat inhaler once daily, at the same time of the day.
Two puffs from Respimat inhaler comprise one medicinal dose.

Administration form

Inhalation

Dosage form

Inhalation solution

Pack sizes

Single pack: 1 Respimat® reusable inhaler and 1 cartridge, providing 60 puffs (30 medicinal doses)
Single refill pack: 1 cartridge, providing 60 puffs (30 medicinal doses)
Reference

1.

SPIOLTO® Respimat® Summary of Product Characteristics.

PC-GB-102131 V2

March 2023

Reporting adverse events

Adverse events should be reported. Reporting form and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone).

Please be aware that this website contains promotional information about Boehringer Ingelheim medicines and services. Some of this may not be directly relevant to your scope of practice and it is your own decision whether you choose to view this information.